entertainment -WSS

entertainment

author：leisure time 2025-09-29 22:50:45 - browse：5

Purple AML cells in blood flow — coverage from STAT — Acute myeloid leukemia cells amid blood flow. Adobe

The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy.

While the label means that physicians will have to have a conversation about secondary malignancies occurring after Carvykti treatment, oncologists and CAR-T experts said the label update won’t change anything about the use of Carvykti.

“I do not believe this particular change will have any bearing on patient care,” said Saad Usmani, a myeloma physician and cell therapist at Memorial Sloan Kettering who has also studied Carvykti. That’s partly because physicians already discuss the risk of second cancers due to other cancer therapies including radiation, some targeted therapies, and some chemotherapies, which are necessary in the use of CAR-T. “We do have secondary primary malignancy discussions with patients in the context of transplant and will have to do for CAR-T as well,” Usmani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

hotspot

WSS

New lawsuit accuses health insurer Cigna of denying claims in bulk

Supreme Court mifepristone arguments center on docs' right to sue

Washington mulls new rules to avert another Change Healthcare

The battle over 'scope creep' and who gets to be called 'doctor'

Patient advocates debate FDA's accelerated approval process

States should stop sabotaging methadone treatment reform

leisure time

entertainment

focus

Novavax promises a turnaround & Lilly roils the obesity market

There's no autism epidemic. It's an autism diagnosis epidemic

At least 13 dead in Texas as scorching temps continue

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Trump demands the U.S. pay no more for drugs than other countries … again

FDA's naming rule on biosimilars has undermined competition

Hollywood unions extend contract negotiations for actors

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Dems pitch expanding Medicare power to negotiate drug prices

focus

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Truvian presents data for its desktop blood

Dems pitch expanding Medicare power to negotiate drug prices

The Readout: Lenmeldy, GLP

Abortion pill case raises question: who can sue the FDA?

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

hotspot

hotspot

leisure time

hotspot